The advantage of health-related quality of life (HRQoL) in continent (C) urinary diversions (UD) over non-continent (NC) UD remains controversial. We compared outcomes by UD type following radical cystectomy (RC) in patients from the RAZOR trial; a multicenter, open-label non-inferiority phase III randomized trial comparing robot-assisted radical cystectomy (RARC) to open cystectomy (OC).
INTRODUCTION AND OBJECTIVES:
The advantage of health-related quality of life (HRQoL) in continent (C) urinary diversions (UD) over non-continent (NC) UD remains controversial. We compared outcomes by UD type following radical cystectomy (RC) in patients from the RAZOR trial; a multicenter, open-label non-inferiority phase III randomized trial comparing robot-assisted radical cystectomy (RARC) to open cystectomy (OC).
METHODS: HRQoL was evaluated using the Functional Assessment of Cancer Therapy-Vanderbilt Cystectomy Index (FACT-VCI) and the SF-8 [with a physical (PCS) and a mental (MCS) component scores]. All questionnaires were administered at baseline, 3-and 6-months (mo) postoperatively. All UD were extracorporeal and determined per patient and surgeon preference. For each endpoint we estimated means by arm and time and by type of diversion and time adjusted for key covariates. We report estimated means with corresponding 95% confidence interval, and p-values adjusted for multiple comparisons among estimated means using the Bonferroni's method, in the per-protocol population.
RESULTS: Sixty-seven patients (22.2%) had CUD (24.7% and 19.7% from the RARC and OC arms, respectively) and 235 (77.8%) a NCUD (75.3% and 80.3% from the RARC and OC arms, respectively). There was no difference between UD groups at any time point for FACT-VCI scores (Table 1A) . CUD group showed a significant improvement in social and emotional well-being (SWB and EWB) at 3 mo but a significant worsening of FACT Bl-Cys score. The NCUD group showed statistically significant improvement at 3-and 6-mo vs baseline in the EWB as well as in all derived scores. SF-8 scores showed an improvement in both groups after surgery (Table 1B) . There was no statistically significant difference between diversion types (p>0.05) for MCS. However, for PCS there was a significant difference between diversion types at 6 mo (PCS mean 51.8 for CUD vs. 46.2 for NCUD, adjusted p[0.019).
CONCLUSIONS: Our data from the RAZOR trial shows no relevant differences between CUD and NCUD with respect to QOL at any time point up to 6 months. Future adequately powered studies will help guide personalized selection of an appropriate UD for each case.
Source of Funding:
The RAZOR trial was supported by the National Institutes of Health (NIH) National Cancer Institute (NCI; grant number 5RO1CA155388).
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INTRODUCTION AND OBJECTIVES:
In an effort to assess and improve quality of care, the Commission on Cancer (CoC) developed three evidence-based quality measures (QMs) for the treatment of muscle invasive bladder cancer (MIBC). These measures include timely administration of treatment; receipt of neoadjuvant or adjuvant chemotherapy; and lymphadenectomy at the time of cystectomy. In this study we assessed performance of these QMs prior to their CoC implementation, whether QMs were associated with overall survival (OS), and whether patient factors influenced the receipt of these QMs.
METHODS: Using the National Cancer Database (NCDB) we identified all patients age 18-90 years old with MIBC (cT2-4N0M0) from 2004 to 2015. Compliance with QMs was recorded. Both univariate and multivariate analyses were utilized to assess the effect of QM compliance on OS as well as patient level predictors of compliance.
RESULTS: A total of 46,502 patients were identified for analysis. Of these, 22,218 (47.8%) underwent radical or partial cystectomy, 5,282 (11.4%) received trimodal therapy, and 19,002 (40.9%) received no treatment. All three QMs were achieved in 44.9% of the surgical cohort and compliance was associated with improved 30-day (HR 0.32, p<0.01), 90-day (HR 0.40, p<0.01), and all-cause mortality (HR 0.82, p<0.01) via univariate and multivariate analyses. Time <90 days to trimodal therapy was achieved in 35.0% of patients and did not improve all-cause mortality (HR 0.93, p[0.07) . In the surgical cohort, predictors of compliance with all 3 metrics included Medicaid (OR 1.26, p[0.05) or other governmental insurance (OR 1.61, p<0.01), higher income (OR 1.27, p<0.01), and living in a low-education zip
